Abbott launches dorsal root ganglion neurostim system in Europe

Abbott (NYSE:ABT) said today that it launched its Proclaim dorsal root ganglion neurostimulation system in Europe for patients suffering from chronic neuropathic pain. The Abbott Park, Il.-based company’s system targets sensory nerves packed within the dorsal root ganglion to directly target the area of the body where pain occurs and provide stronger pain relief compared to traditional spinal cord stimulation therapy. “Many patients battling chronic neuropathic pain have not found adequate relief from other forms of treatment, which is why dorsal root ganglion stimulation has been such an important therapeutic advancement for pain specialists worldwide,” Dr. Harold Nijhuis, an anesthesiologist from the Netherlands, said in prepared remarks. “With the approval of the Proclaim DRG System, I am able to address chronic focal pain for my patients while offering them access to new, patient-centric benefits and features to improve their therapy experience.” Abbott claims it is the only company to offer a neurostim device designed for DRG therapy. Patients with chronic neuropathic pain can access the company’s Proclaim platform and an iPod touch mobile digital device patient controller that features wireless communication via Bluetooth. “Abbott continues to pursue innovative solutions for chronic pain because far too many patients with chronic intractable pain battle symptoms that are not adequately managed with current therapies,” Abbo...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Neuromodulation/Neurostimulation Pain Management Regulatory/Clearance Wall Street Beat Abbott Source Type: news

Related Links:

Complex regional pain syndrome (CRPS) type I and CRPS type II diminish quality of life and can lead to significant disability.15 Both conditions have varied and complex clinical features, with chronic debilitating pain being the primary symptom, usually involving the lower or upper extremities.16,24 The conditions are differentiated by the absence (CRPS-I) or presence (CRPS-II) of demonstrable nerve damage as an underlying etiology.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research
We examined the expression of TRPV1 in peripheral tissue and DRG neurons of CPIP model rats and we studied whether CPIP model could induce peripheral sensitization of TRPV1 channel and enhance DRG neuron excitability. Then we examined the therapeutic effects of locally applied TRPV1 specific antagonist AMG9810 on pain responses of CPIP model rats. Lastly, we explored the effects of AMG9810 on DRG neuron hyperexcitability and spinal glial activation induced by CPIP. Our results demonstrate that TRPV1 plays an important role in mediating the behavioral hypersensitivity of CPIP model rats via promoting peripheral nociceptor a...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionsSome DRG subjects achieved effective paresthesia ‐free analgesia in the ACCURATE trial. This supports the observation that paresthesia is not synonymous with pain relief or required for optimal analgesia with DRG stimulation.
Source: Neuromodulation: Technology at the Neural Interface - Category: Biotechnology Authors: Tags: Clinical Research Source Type: research
ConclusionsDRG stimulation significantly reduced the severity of subjects' pain and enabled participatory changes that improved quality of life through 12 ‐months postimplant.
Source: Neuromodulation: Technology at the Neural Interface - Category: Biotechnology Authors: Tags: Clinical Research Source Type: research
Abbott Laboratories has nabbed approvals for a chronic pain treatment device that patients can try before getting an implanted version of the technology. The Dorsal Root Ganglion (DRG) Invisible Trial System now has CE mark and a nod from FDA. The Abbott Park, IL-based company said patients who find adequate pain relief with DRG therapy can then have the Proclaim DRG System implanted. The Proclaim DRG includes an implantable neuromodulator that stimulates the dorsal root ganglion (DRG), an Apple iPad for programming the device, and an iPod touch for the patient control of the device. “Abbott's DRG Invisib...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
AbstractPurpose of ReviewThe purpose of this article is to illustrate the recent advances made in the field of neuromodulation for chronic pain management and it provides a brief review of the literature supporting their safe and efficacious use.Recent FindingsSpinal cord stimulation (SCS) has been an effective therapy for the management of intractable pain conditions including complex regional pain syndrome (CRPS), peripheral neuropathy, and failed back surgery syndrome (FBSS). With the introduction of high-frequency and burst SCS waveforms, there has been a noted improvement in the treatment outcomes of these pain syndro...
Source: Current Anesthesiology Reports - Category: Anesthesiology Source Type: research
Purpose of review To update the recent development of spinal cord stimulation (SCS) technology in the management of chronic pain. Recent Findings Efficacy of SCS therapy has been significantly improved by the recent development of high frequency (HF-10 kHz) stimulation, burst stimulation, and dorsal root ganglion (DRG) stimulation. A few latest SCS modalities are in clinical trial. New approaches to guide lead placement and advances in surgical lead are introduced. Summary HF-10 SCS is free of paresthesia and associated with significantly better coverage of axial lower back pain. Burst stimulation invokes minimal...
Source: Current Opinion in Anaesthesiology - Category: Anesthesiology Tags: TECHNOLOGY, EDUCATION AND SAFETY: Edited by Yandong Jiang and Merrick E. Miles Source Type: research
Abbott is releasing in the U.S. its Proclaim DRG neurostimulation system to fight chronic pain in patients with complex regional pain syndrome in their legs. The product consists of an implantable neuromodulator that stimulates the dorsal root gangli...
Source: Medgadget - Category: Medical Devices Authors: Tags: Neurology Neurosurgery Pain Management Source Type: blogs
Abbott (NYSE:ABT) said today it launched its Proclaim dorsal root ganglion neurostimulator system designed to treat pain in patients with complex regional pain syndrome of the lower limbs. The company’s Proclaim DRG system is designed to be used via Bluetooth with an Apple (NSDQ:AAPL) iPod touch as a system controller and is magnetic resonance-conditional and recharge free, all upgrades from previous versions of the device, the Abbott Park, Ill.-based company said. Abbott said it originally launched the DRG therapy system in 2016 and data from the Accurate study of it showed the system delivers “...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Neuromodulation/Neurostimulation Pain Management Abbott Source Type: news
Abbott (NYSE:ABT) today touted short- and long-term data published in the journal Pain, which demonstrated that its dorsal root ganglion stimulation therapy benefits patients suffering from complex regional pain syndrome more than traditional spinal cord stimulation. The Abbott Park, Ill.-based company said it’s the only company in the world approved to offer DRG stimulation. The newly-published data is from the company’s ACCURATE study, which evaluated DRG stimulation in patients for 3 and 12 months. “Historically, many patients with chronic pain resulting from complex regional pain syndrome or...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Pain Management Research & Development Spinal Abbott Source Type: news
More News: Anesthesia | Anesthesiology | Back Pain | Chronic Pain | Complex Regional Pain Syndrome | Ganglions | Neurology | Pain | Pain Management | Statistics | Study